Canbex Therapeutics Overview

  • Status
  • Acquired/​Merged

  • Employees
  • 4

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $109M

  • Investors
  • 1

Canbex Therapeutics General Information

Description

Operator of a drug development company based in London, United Kingdom The company provides cannabinoid agonists for the treatment of spasticity in multiple sclerosis and other related disorders.

Contact Information

Formerly Known As
Aximygen Limited
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • London BioScience Innovation Centre
  • 2 Royal College Street
  • London NW1 0NH
  • England, United Kingdom
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
Vertical(s)
Corporate Office
  • London BioScience Innovation Centre
  • 2 Royal College Street
  • London NW1 0NH
  • England, United Kingdom

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Canbex Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Merger/Acquisition 24-Feb-2015 $109M Completed Generating Revenue
4. Grant 06-Sep-2013 Completed Generating Revenue
3. Later Stage VC (Series A) 11-Apr-2013 Completed Generating Revenue
2. Early Stage VC Completed Startup
1. University Spin-Out 01-Mar-2004 Completed Startup
To view Canbex Therapeutics’s complete valuation and funding history, request access »

Canbex Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
Ordinary 2
Ordinary 1 172,580 $4.43 $4.43 1x $4.43 22.23%
To view Canbex Therapeutics’s complete cap table history, request access »

Canbex Therapeutics Patents

Canbex Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-201516494-D0 New therapeutic use Inactive 17-Sep-2015
EP-3256122-A1 Bkca channel activator for treating muscular disorder Inactive 13-Feb-2015
US-20180021303-A1 Bkca channel activator for treating muscular disorder Inactive 13-Feb-2015
WO-2016128772-A1 Bkca channel activator for treating muscular disorder Inactive 13-Feb-2015
EP-3256112-A1 Compounds for treating disorders associated with bk channel modulation Inactive 13-Feb-2015 A61K31/166
To view Canbex Therapeutics’s complete patent history, request access »

Canbex Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Canbex Therapeutics Former Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
Bloomsbury Bioseed Fund Venture Capital Minority
Esperante Ventures Corporate Venture Capital Minority
M Ventures Corporate Venture Capital Minority
UCL Ventures University Minority
Wellcome Trust Limited Partner Minority
To view Canbex Therapeutics’s complete investors history, request access »

Canbex Therapeutics FAQs

  • Where is Canbex Therapeutics headquartered?

    Canbex Therapeutics is headquartered in London, United Kingdom.

  • What is the size of Canbex Therapeutics?

    Canbex Therapeutics has 4 total employees.

  • What industry is Canbex Therapeutics in?

    Canbex Therapeutics’s primary industry is Drug Discovery.

  • Is Canbex Therapeutics a private or public company?

    Canbex Therapeutics is a Private company.

  • What is the current valuation of Canbex Therapeutics?

    The current valuation of Canbex Therapeutics is .

  • What is Canbex Therapeutics’s current revenue?

    The current revenue for Canbex Therapeutics is .

  • How much funding has Canbex Therapeutics raised over time?

    Canbex Therapeutics has raised $4.99M.

  • Who are Canbex Therapeutics’s investors?

    Bloomsbury Bioseed Fund, Esperante Ventures, M Ventures, UCL Ventures, and Wellcome Trust have invested in Canbex Therapeutics.

  • When was Canbex Therapeutics acquired?

    Canbex Therapeutics was acquired on 24-Feb-2015.

  • Who acquired Canbex Therapeutics?

    Canbex Therapeutics was acquired by Ipsen.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process